MAZE Maze Therapeutics, Inc.
MAZE Maze Therapeutics, Inc.
Healthcare · Biotechnology
Market read
POC $27.27 · VWAP $31.72 · -11.9% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
MAZE Price Structure
Loading timeframes…
Peers
Every watchlist MAZE belongs to, members best 30-day change first — MAZE highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported EPS $-0.76 versus analyst consensus of $-0.70 (-9.2%).
full note →Against street estimates
How MAZE's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about MAZE from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 58 days ago · Jun 21
- Maze Therapeutics to Participate in Two Upcoming Investor Conferences
- Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CEO Sells 1,938 Shares of Stock
- MAZE Q1 2026 Earnings: EPS Beat but Stock Slips as Pre-Revenue Biotech Navigates Clinical Pipeline
- Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Maze Therapeutics Q1 2026: HORIZON data, cash 2029 | MAZE Stock News
MAZE research tape
6 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.